Company profile
ATARA BIOTHERAPEUTICS, INC.
NASDAQ:ATRABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EVRULEUCEL | phase1_2 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06256484 | phase1 | terminated | 2024-09-06 | 2025-03-03 | Atara Biotherapeutics | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
| NCT06429800 | phase1 | withdrawn | 2025-04-16 | 2025-04-16 | Atara Biotherapeutics | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus |
| NCT00002663 | phase1_2 | completed | 1995-03-01 | 2019-07-01 | Atara Biotherapeutics | Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies |
| NCT03283826 | phase1_2 | terminated | 2017-10-19 | 2023-11-09 | Atara Biotherapeutics | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis |
| NCT03769467 | phase1_2 | terminated | 2019-02-19 | 2021-08-19 | Atara Biotherapeutics | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
FDA applications (0)
No records yet.